ProfileGDS5678 / 1440135_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 62% 61% 62% 60% 60% 64% 63% 61% 60% 60% 60% 60% 65% 61% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 13.7598162
GSM967853U87-EV human glioblastoma xenograft - Control 23.641761
GSM967854U87-EV human glioblastoma xenograft - Control 33.7283962
GSM967855U87-EV human glioblastoma xenograft - Control 43.5252660
GSM967856U87-EV human glioblastoma xenograft - Control 53.5535760
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 13.8816664
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 23.8653563
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 33.6462761
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 43.5682860
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 13.6020860
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 23.6137360
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 33.5734760
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 43.9094165
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 53.6247661